Darren B. Taichman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Darren B. Taichman has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Harold I. Palevsky
Department of Medicine and
3 shared publications - Christine Archer-Chicko
Department of Medicine and
2 shared publications - Jess Mandel
School of Medicine, University of California San Diego, La Jolla, CA, USA
2 shared publications - John Hansen-Flaschen
Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2 shared publications - Michael Oscar Harhay
University of Pennsylvania
2 shared publications - Sandra Kaplan
Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, University of Pennsylvania Medical Center-Presbyterian, Philadelphia, PA 19104, USA
2 shared publications
Latest Publications
- 1 December 2013
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 34 (4) , 619-637
Epidemiology of Pulmonary Arterial Hypertension
- 1 December 2013
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 34 (4) , 619-637
Epidemiology of Pulmonary Arterial Hypertension
- 5 October 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 153 (7) , 480-481
Whose Funeral Is It Anyway?
- 5 October 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 153 (7) , 480-481
Whose Funeral Is It Anyway?
- 1 July 2009
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 84 (7) , 586-592
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
- 1 July 2009
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 84 (7) , 586-592
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
- 21 October 2008
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (8) , 583-585
Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?
- 21 October 2008
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (8) , 583-585
Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?
- 11 July 2008
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (10) , 1431-1438
Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension
- 11 July 2008
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (10) , 1431-1438
Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension
- 1 March 2007
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 28 (1) , 1-22
Epidemiology of Pulmonary Arterial Hypertension
- 1 March 2007
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 28 (1) , 1-22
Epidemiology of Pulmonary Arterial Hypertension
- Open Access
- 10 August 2005
- Published by Springer Nature in Respiratory Research
- Vol. 6 (1) , 92
Health-related quality of life in patients with pulmonary arterial hypertension
Background: Improved outcomes with expanding treatment options for patients with pulmonary arterial hypertension present the opportunity to consider additional end-points in approaching therapy, including factors that influence health-related quality of life. However, comparatively little is known about health-related quality of life and its determinants in patients with pulmonary arterial hypertension. Methods: Health-related quality of life was evaluated in a cross sectional study of 155 outpatients with pulmonary arterial hypertension using generic and respiratory-disease specific measurement tools. Most patients had either World Health Organization functional Class II or III symptoms. Demographic, hemodynamic and treatment variables were assessed for association with health-related quality of life scores. Results: Patients with pulmonary arterial hypertension suffered severe impairments in both physical and emotional domains of health-related quality of life. Patients with idiopathic ("primary") pulmonary arterial hypertension had the best, and those with systemic sclerosis the worst health-related quality of life. Greater six-minute walk distance correlated with better health-related quality of life scores, as did functional Class II versus Class III symptoms. Hemodynamic measurements, however, did not correlate with health-related quality of life scores. No differences in health-related quality of life were found between patients who were being treated with calcium channel antagonists, bosentan or continuously infused epoprostenol at the time of quality of life assessment. Conclusion: Health-related quality of life is severely impaired in patients with pulmonary arterial hypertension and is associated with measures of functional status. Specific associations with impaired health-related quality of life suggest potential areas for targeted intervention.
- 10 August 2005
- Published by Springer Nature in Respiratory Research
- Vol. 6 (1) , 92
Open AccessHealth-related quality of life in patients with pulmonary arterial hypertension
Background: Improved outcomes with expanding treatment options for patients with pulmonary arterial hypertension present the opportunity to consider additional end-points in approaching therapy, including factors that influence health-related quality of life. However, comparatively little is known about health-related quality of life and its determinants in patients with pulmonary arterial hypertension. Methods: Health-related quality of life was evaluated in a cross sectional study of 155 outpatients with pulmonary arterial hypertension using generic and respiratory-disease specific measurement tools. Most patients had either World Health Organization functional Class II or III symptoms. Demographic, hemodynamic and treatment variables were assessed for association with health-related quality of life scores. Results: Patients with pulmonary arterial hypertension suffered severe impairments in both physical and emotional domains of health-related quality of life. Patients with idiopathic ("primary") pulmonary arterial hypertension had the best, and those with systemic sclerosis the worst health-related quality of life. Greater six-minute walk distance correlated with better health-related quality of life scores, as did functional Class II versus Class III symptoms. Hemodynamic measurements, however, did not correlate with health-related quality of life scores. No differences in health-related quality of life were found between patients who were being treated with calcium channel antagonists, bosentan or continuously infused epoprostenol at the time of quality of life assessment. Conclusion: Health-related quality of life is severely impaired in patients with pulmonary arterial hypertension and is associated with measures of functional status. Specific associations with impaired health-related quality of life suggest potential areas for targeted intervention.
- Open Access
- 25 April 2005
- Published by Springer Nature in Respiratory Research
- Vol. 6 (1) , 39
Validation of a brief telephone battery for neurocognitive assessment of patients with pulmonary arterial hypertension
Background: The effects of pulmonary arterial hypertension on brain function are not understood, despite patients' frequent complaints of cognitive difficulties. Using clinical instruments normally administered during standard in-person assessment of neurocognitive function in adults, we assembled a battery of tests designed for administration over the telephone. The purpose was to improve patient participation, facilitate repeated test administration, and reduce the cost of research on the neuropsychological consequences of acute and chronic cardiorespiratory diseases. We undertook this study to validate telephone administration of the tests. Methods: 23 adults with pulmonary arterial hypertension underwent neurocognitive assessment using both standard in-person and telephone test administration, and the results of the two methods compared using interclass correlations. Results: For most of the tests in the battery, scores from the telephone assessment correlated strongly with those obtained by in-person administration of the same tests. Interclass correlations between 0.5 and 0.8 were observed for tests that assessed attention, memory, concentration/working memory, reasoning, and language/crystallized intelligence (p ≤ 0.05 for each). Interclass correlations for the Hayling Sentence Completion test of executive function approached significance (p = 0.09). All telephone tests were completed within one hour. Conclusion: Administration of this neurocognitive test battery by telephone should facilitate assessment of neuropsychological deficits among patients with pulmonary arterial hypertension living across broad geographical areas, and may be useful for monitoring changes in neurocognitive function in response to PAH-specific therapy or disease progression.
- 25 April 2005
- Published by Springer Nature in Respiratory Research
- Vol. 6 (1) , 39
Open AccessValidation of a brief telephone battery for neurocognitive assessment of patients with pulmonary arterial hypertension
Background: The effects of pulmonary arterial hypertension on brain function are not understood, despite patients' frequent complaints of cognitive difficulties. Using clinical instruments normally administered during standard in-person assessment of neurocognitive function in adults, we assembled a battery of tests designed for administration over the telephone. The purpose was to improve patient participation, facilitate repeated test administration, and reduce the cost of research on the neuropsychological consequences of acute and chronic cardiorespiratory diseases. We undertook this study to validate telephone administration of the tests. Methods: 23 adults with pulmonary arterial hypertension underwent neurocognitive assessment using both standard in-person and telephone test administration, and the results of the two methods compared using interclass correlations. Results: For most of the tests in the battery, scores from the telephone assessment correlated strongly with those obtained by in-person administration of the same tests. Interclass correlations between 0.5 and 0.8 were observed for tests that assessed attention, memory, concentration/working memory, reasoning, and language/crystallized intelligence (p ≤ 0.05 for each). Interclass correlations for the Hayling Sentence Completion test of executive function approached significance (p = 0.09). All telephone tests were completed within one hour. Conclusion: Administration of this neurocognitive test battery by telephone should facilitate assessment of neuropsychological deficits among patients with pulmonary arterial hypertension living across broad geographical areas, and may be useful for monitoring changes in neurocognitive function in response to PAH-specific therapy or disease progression.